Amarin Corp Plcuk (AMRN) EBIT Growth (1y) (2011 - 2026)
Amarin Corp Plcuk (AMRN) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.34% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -9.81% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 32.30% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -520.13% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -15.58% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -76.09% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 24.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.87% |
| Mar 31, 2026 | 32.35% |
| Dec 31, 2025 | 87.96% |
| Sep 30, 2025 | 55.88% |
| Jun 30, 2025 | -2,950.57% |
| Mar 31, 2025 | -23.35% |
| Dec 31, 2024 | -985.84% |
| Sep 30, 2024 | -17.33% |
| Jun 30, 2024 | 97.81% |
| Mar 31, 2024 | 21.67% |
| Dec 31, 2023 | 49.54% |
| Sep 30, 2023 | -317.01% |
| Jun 30, 2023 | 61.87% |
| Mar 31, 2023 | 38.74% |
| Dec 31, 2022 | -159.42% |
| Sep 30, 2022 | 60.65% |
| Jun 30, 2022 | -816.20% |
| Mar 31, 2022 | -2,026.75% |
| Dec 31, 2021 | 125.38% |
| Sep 30, 2021 | -88.37% |